Unknown君 Launches New FMT Product Portfolio with Standard FMT Now Available

On March 31, Xbiome officially launched a new FMT (fecal microbiota transplantation) product matrix covering a wider population and addressing more diverse health management needs; simultaneously, it announced that the matrix includes three major products—Standard Edition FMT, Precision Edition FMT, and Super Edition FMT Officially Launched.The products launched this time achieve full-level coverage from basic sub-health repair to high-end personalized, long-term health management, allowing Xbiome's leading FMT research results and high-quality products produced according to global top standards to serve consumers' health.

In recent years, the value of the intestinal microecology to human diseases and health has been widely recognized by the global scientific and medical communities. Data shows that 70% of the population in China suffers from intestinal sub-health problems to varying degrees, and the demand for intestinal barrier repair, immune regulation, and sub-health improvement has shown explosive growth. FMT achieves the treatment of intestinal and extra-intestinal diseases as well as health improvement by transplanting functional flora from the feces of healthy individuals into the patient's gastrointestinal tract to rebuild a healthy intestinal flora.

In 2013, FMT was officially regulated by the U.S. FDA, and in 2023, it was included in the "National Technical Specifications for Medical Service Projects" by three departments, including China's National Health Commission. Currently, more than 20 provinces and municipalities in China have issued relevant charge codes. The official recognition, clinical effectiveness, and industrialization progress of FMT fecal microbiota transplantation technology have all accelerated comprehensively.

As a leading company in China's microecology field, Xbiome's newly released FMT matrix ensures that each product and every treatment course is produced by Asia's leading AI microbiome research platform, utilizing a production system regulated and recognized by the U.S. FDA, and meeting both GMP and cGMP dual standards. In addition, they are endorsed by scientific research achievements in collaboration with top hospitals and clinical experts in China, while also fully responding to consumers' various usage scenarios and different health needs.

Standard Edition FMTBy using standardized products, we can modulate the gut microbiota, repair the intestinal barrier at its source, reduce intestinal inflammation, and improve overall health, making FMT more accessible and affordable.Precision FMTCustomized Reconstruction of Intestinal Microecology with AI Precision Matching and Pharmaceutical-Grade Active Bacterial Clusters to Precisely Address Specific Health Issues;Super Version FMTBased on the Precision Edition product, it provides long-term one-on-one health management services from authoritative functional medicine experts for high-end users, continuously optimizing and refining the maintenance of gut microbiota to achieve dynamic preservation and improvement of overall health.

Standard Edition FMT Positioning"Intestinal Origin Sub-health Restoration Engineer"， Each course of treatment consists of 30 lyophilized powder capsules, primarily targeting sub-healthy individuals aged 30-65 who have a desire to improve their health. The aim is to repair the intestinal barrier from the source, regulate the balance of gut microbiota, reduce chronic intestinal inflammation, and specifically address common sub-health issues such as intestinal discomfort, low immunity, fatigue, and poor sleep quality through a standardized universal microbiome formula.

In the form of oral capsules, no enema or medical examination is required. It can be taken at home and fits into daily health management scenarios for the general public.

In addition to the standard version of FMT, Xbiome has launched simultaneously.Precision FMT and Super FMTProducts. Two advanced versions of the products, targeting personalized health needs at different levels, create differentiated high-end solutions, forming a complete product lineup to meet the more diverse health demands of different populations.

The Precision Edition of FMT Positions Itself as the "Architect of Precision Gut Microecology Reconstruction," Primarily Targeting Individuals with Specific Health Improvement Needs and a Pursuit of High-Quality, Customized Solutions.The product relies on Xbiome's self-developed AI-driven precision donor-recipient matching algorithm, and based on users' gut microbiota testing data, matches users with their exclusive "optimal donor" to achieve"One Person, One Solution"Customized Gut Microbiome Renewal. Each treatment course provides two dosage forms: 30 frozen liquid capsules or 60ml of bacterial solution, while creating a complete service loop from gut microbiota testing, AI matching, fecal microbiota transplantation to efficacy quantification assessment. Optional personalized health management services are also available to precisely address specific health needs of users.

Super FMT: Positioned as the "Comprehensive Gut Health Long-term Management Expert," it primarily targets high-net-worth individuals with premium health aspirations such as anti-aging, weight management, and intestinal rejuvenation, who have the highest demands for health management.On the basis of the core functions of precise FMT testing, matching, transplantation, and efficacy evaluation, the product has comprehensively upgraded its service system and assigned...Authoritative functional medicine experts provide one-on-one exclusive health management services for users.Create a long-cycle micro-ecological health management solution that goes beyond the treatment course itself, achieving dynamic tracking, continuous optimization, and long-term value-added health status. Product specifications: >30 frozen liquid capsules per treatment course.

Every product in Xbiome's new FMT product matrix embodies the company’s solid commitment to consumers—backed by Asia-leading FMT drug application progress, abundant scientific research achievements co-created with experts across China, a quasi-pharmaceutical-grade GMP production system, and an advanced AI algorithm platform.

As a national high-tech enterprise and a specialized and innovative small and medium-sized enterprise in Shenzhen, Xbiome has independently built a leading AI microbiome research and industrial transformation platform.It is the first pharmaceutical company in Asia to obtain the FDA's IND for fecal microbiota transplantation and the first in China to obtain the NMPA's IND for genetically engineered bacterial new drugs.Xbiome has built an FMT donor bank consisting of "0.1% super healthy individuals," possessing a quasi-pharmaceutical-grade production system that meets U.S. FDA regulatory standards and holds both GMP and cGMP certifications. It has independently developed an AI donor-recipient matching algorithm and a disease classification risk prediction model, leading the industry in core technological capabilities within China and Asia.

The launch of the new FMT product matrix marks an important milestone for the company as it extends from microbiome pharmaceuticals into the health management field. Moving forward, Xbiome will continue to focus on AI and BT-driven scientific research in the human gut microbiome, accelerating technological innovation and transformation. With the scientific mechanisms and production standards of biopharmaceuticals, Xbiome will bring brand and product value upgrades to high-end healthcare partners.

-End-